Treatment changes do not reduce weight in people with HIV
Simpler PrEP services – fewer check-ups, online care – work as well as the standard approach
HIV acquisition in women with good adherence to TAF/FTC PrEP is rare
New long-acting HIV drugs show promising early results
Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
Studies confirm non-inferiority of doravirine / islatravir to standard HIV treatment
PEPFAR study shows the deadly impact of stopping children’s HIV treatment
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
